MX2022000598A - Preparacion de compuestos antibacterianos. - Google Patents

Preparacion de compuestos antibacterianos.

Info

Publication number
MX2022000598A
MX2022000598A MX2022000598A MX2022000598A MX2022000598A MX 2022000598 A MX2022000598 A MX 2022000598A MX 2022000598 A MX2022000598 A MX 2022000598A MX 2022000598 A MX2022000598 A MX 2022000598A MX 2022000598 A MX2022000598 A MX 2022000598A
Authority
MX
Mexico
Prior art keywords
ridinilazole
preparation
crystalline forms
processes
bibenzo
Prior art date
Application number
MX2022000598A
Other languages
English (en)
Inventor
Francis Xavier Wilson
Jean-Francois Carniaux
Nigel Adams
Original Assignee
Summit Oxford Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1910250.8A external-priority patent/GB201910250D0/en
Priority claimed from GBGB1912144.1A external-priority patent/GB201912144D0/en
Application filed by Summit Oxford Ltd filed Critical Summit Oxford Ltd
Publication of MX2022000598A publication Critical patent/MX2022000598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen los procesos para la preparación de 2,2'-di(piridin-4-il)-1H,1'H-5,5'-bibenzo[d]imidazol (que además se puede conocer como 5,5'bis-[2-(4-piridinil)-1H-bencimidazol]), al que se hace referencia en la presente descripción con el nombre INN ridinilazol y derivados, sales, hidratos, solvatos, complejos, bioisósteros, metabolitos o profármacos farmacéuticamente aceptables de este. La invención se refiere además a diversas composiciones de ridinilazol purificado, a diversas formas cristalinas de ridinilazol, a procesos para su preparación y a preparaciones farmacéuticas relacionadas y usos de estas (que incluyen su uso médico y su uso en la síntesis efectiva a gran escala de ridinilazol).
MX2022000598A 2019-07-17 2020-07-16 Preparacion de compuestos antibacterianos. MX2022000598A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1910250.8A GB201910250D0 (en) 2019-07-17 2019-07-17 Preparation of antibacterial compounds
GBGB1912144.1A GB201912144D0 (en) 2019-08-23 2019-08-23 Antibacterial compounds
PCT/GB2020/051710 WO2021009514A1 (en) 2019-07-17 2020-07-16 Process for the preparation of ridinilazole and crystalline forms thereof

Publications (1)

Publication Number Publication Date
MX2022000598A true MX2022000598A (es) 2022-03-04

Family

ID=72148169

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000598A MX2022000598A (es) 2019-07-17 2020-07-16 Preparacion de compuestos antibacterianos.

Country Status (11)

Country Link
US (1) US20220289705A1 (es)
EP (1) EP3999502A1 (es)
JP (1) JP2022542822A (es)
KR (1) KR20220024617A (es)
CN (1) CN114127056A (es)
AU (1) AU2020315188A1 (es)
BR (1) BR112022000484A2 (es)
CA (1) CA3146788A1 (es)
IL (1) IL289453A (es)
MX (1) MX2022000598A (es)
WO (1) WO2021009514A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202100471D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
WO2023213878A1 (en) * 2022-05-04 2023-11-09 Summit (Oxford) Limited Solid tablet dosage form of ridinilazole

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09512831A (ja) 1994-11-17 1997-12-22 エフ・ホフマン−ラ ロシュ アーゲー ジベンズイミダゾール誘導体
MXPA03005298A (es) 2000-12-15 2003-10-06 Vertex Pharma Inhibidores de girasa y usos de los mismos.
CA2489128C (en) 2002-06-13 2012-01-03 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
JP2006513162A (ja) 2002-11-01 2006-04-20 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用方法
WO2006076009A2 (en) 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
US8394803B2 (en) 2005-11-07 2013-03-12 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
PT2575968E (pt) * 2010-06-01 2016-06-20 Summit Therapeutics Plc Compostos para o tratamento de doença associada com clostridium difficile
WO2011151618A2 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
KR20160143842A (ko) * 2014-04-22 2016-12-14 아르퀼 인코포레이티드 치환된 이미다조피리디닐-아미노피리딘 화합물의 염 및 다형체
CN111315736B (zh) 2017-10-05 2023-07-07 桑多斯股份公司 使用酸加成盐制备雷地尼唑的方法

Also Published As

Publication number Publication date
AU2020315188A1 (en) 2022-02-10
CN114127056A (zh) 2022-03-01
JP2022542822A (ja) 2022-10-07
CA3146788A1 (en) 2021-01-21
US20220289705A1 (en) 2022-09-15
BR112022000484A2 (pt) 2022-03-08
IL289453A (en) 2022-02-01
KR20220024617A (ko) 2022-03-03
WO2021009514A1 (en) 2021-01-21
EP3999502A1 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
CR20220230A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
MX2022006475A (es) Compuestos triciclicos sustituidos.
MX2010007375A (es) Nuevos derivados de lupano.
YU30702A (sh) Novi derivati benzoimidazola, korisni agensi protiv proliferacije
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
MX2010003868A (es) Cis-imidazolinas quirales.
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
MX2013003036A (es) Derivados de pirazina como bloqueadores de enac.
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
MX2021004000A (es) Derivados de piperidina.
MX344109B (es) Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico.
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2022000598A (es) Preparacion de compuestos antibacterianos.
MX2010013310A (es) Derivados de heterociclil urea para el tratamiento de infecciones bacterianas.
JOP20220063A1 (ar) مشتقات بيريدازين-3(2h)-أون ملتحمة بأزول
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
JO2749B1 (en) Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application
MX2022007518A (es) Derivados bencimidazol.
ZA202203107B (en) Azaindole carboxamide compounds for the treatment of mycobacterial infections
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
CA3155875A1 (en) BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE
MX2021009206A (es) Terapias contra el cancer.
ZA202203108B (en) Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections